NDAORALCAPSULE
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
RIMACTANE (rifampin) by Oxford Drug Design is clinical pharmacology oral administration rifampin is readily absorbed from the gastrointestinal tract. First approved in 1971.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIMACTANE (rifampin) is an oral bactericidal antibiotic that inhibits DNA-dependent RNA polymerase activity in Mycobacterium tuberculosis and other susceptible organisms. It is a foundational drug for tuberculosis treatment and is also used as adjunctive therapy in HIV infection management. Rifampin is rapidly absorbed, widely distributed including to cerebrospinal fluid, and undergoes hepatic metabolism with a half-life of 2–3 hours at steady state.
LOE Approaching
As a foundational tuberculosis agent nearing loss of exclusivity, the brand faces significant generic erosion and shifting commercial focus toward emerging TB regimens and combination therapies.
Mechanism of Action
CLINICAL PHARMACOLOGY Oral Administration Rifampin is readily absorbed from the gastrointestinal tract. Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual. Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum…
Worked on RIMACTANE at Oxford Drug Design? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.